Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 77, Issue 4, Pages 715-728Publisher
WILEY
DOI: 10.1111/bcp.12253
Keywords
calcineurin inhibitors; ciclosporin; kidney transplantation; pharmacogenetics; tacrolimus
Categories
Funding
- Astellas Pharma Inc
- Astellas
- Pfizer
Ask authors/readers for more resources
Pharmacogenetics has generated many expectations for its potential to individualize therapy proactively and improve medical care. However, despite the huge amount of reported genetic associations with either pharmacokinetics or pharmacodynamics of drugs, the translation into patient care is still slow. In fact, strong evidence for a substantial clinical benefit of pharmacogenetic testing is still limited, with a few exceptions. In kidney transplantation, established pharmacogenetic discoveries are being investigated for application in the clinic to improve efficacy and to limit toxicity associated with the use of immunosuppressive drugs, especially the frequently used calcineurin inhibitors (CNIs) tacrolimus and ciclosporin. The purpose of the present review is to picture the current status of CNI pharmacogenetics and to discuss the most promising leads that have been followed so far.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available